1. Minding the Gap Rheumatoid Arthritis Advances From London 2016

2. Disclaimer

3. Program Goal

5. Segment 1: Michael Schiff Abstracts Reviewed

6. Segment 2: Roy Fleischmann Abstracts Reviewed

7. Segment 3: Roy Fleischmann Abstracts Reviewed

8. Concluding Remarks

10. New TNF Inhibitor Formulations and Delivery Methods

11. Abstract #1

12. Study Design

13. Immediate Pain After Injection

14. Impact of Findings

15. Abstract #2

16. Study Design

17. Autoinjection Device Ranking by Patient Preference

18. Impact of Findings

20. Biologic Dose Reductions in Patients with RA

21. Abstract #1

22. Study Design[a]

23. Physical Function and % Patients With Normative Function From Wk 52 to Wk 104

24. Conclusion

25. Abstract #2

26. Study Design[a]

27. Reasons for Dose Reduction in EXTEND

28. Conclusions

30. Effect of Biologic Agents on RF and ACPA Levels

31. Abstract #1

32. Study Design[a]

33. OPTIMA Change in RF and ACPA with Adalimumab Treatment

34. Validating Findings PREMIER

35. Validating Findings DE019

36. Conclusions

37. Abstract #2

38. Study Design[a]

39. ACR20 Incidence in RF and ACPA Subgroups

40. HAQ-DI in RF and ACPA Subgroups

41. Conclusions

42. Abbreviations

43. Abbreviations (cont)